Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.82 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.64 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.63 |
| ▸ | CA9 | Q16790 | 4/20 | 0.63 |
| ▸ | CA1 | P00915 | 3/20 | 0.63 |
| ▸ | CA2 | P00918 | 3/20 | 0.63 |
| ▸ | CA7 | P43166 | 3/20 | 0.63 |
| ▸ | RAF1 | P04049 | 2/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118026 | 0.90 | KDR (1.00) | KDRPDK1TRPV1CA9CA1 | |
| SCHEMBL29364392 | 0.90 | KDR (1.00) | KDRPDK1TRPV1CA9CA1 | |
| SCHEMBL11831657 | 0.88 | KDR (0.62) | KDRPDK1TRPV1CA9CA1 | |
| SCHEMBL19668269 | 0.86 | KDR (0.74) | KDRTRPV1CA9CA1CA2 | |
| SCHEMBL4548158 | 0.86 | KDR (0.90) | KDRPDK1TRPV1CA9CA1 | |
| SCHEMBL13145695 | 0.86 | KDR (0.59) | KDRPDK1TRPV1CA9CA1 | |
| SCHEMBL3644352 | 0.86 | KDR (0.84) | KDRPDK1TRPV1CA9CA1 | |
| SCHEMBL16477690 | 0.85 | KDR (0.77) | KDRPDK1TRPV1CA9CA1 | |
| SCHEMBL13004799 | 0.85 | KDR (0.82) | KDRPDK1TRPV1CA9CA1 | |
| SCHEMBL13556584 | 0.85 | KDR (0.82) | KDRPDK1TRPV1CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3323813-A1 | HISTONE ACETYLTRANSFERASE MODULATORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2018-05-23 | — | — | EP | disclosed |
| WO-2018045969-A1 | COMPOUND FOR ACTIVATING ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE | 法玛科技顾问股份有限公司 | 2018-03-15 | — | — | WO | disclosed |
| US-20170121276-A1 | HISTONE ACETYLTRANSFERASE MODULATORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-05-04 | — | — | US | disclosed |
| US-9216950-B2 | Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same | NATIONAL TAIWAN UNIVERSITY (TW) | 2015-12-22 | — | — | US | disclosed |
| US-9090617-B1 | Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same | NATIONAL TAIWAN UNIVERSITY (TW) | 2015-07-28 | — | — | US | disclosed |
| US-20150191467-A1 | AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME | RAND BIOSCIENCES (KR) | 2015-07-09 | — | — | US | disclosed |
| US-20140200239-A1 | AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME | NATIONAL TAIWAN UNIVERSITY (TW) | 2014-07-17 | — | — | US | disclosed |
| US-7989422-B2 | Antibacterial agents | ALCHEMIA LIMITED (AU) | 2011-08-02 | — | — | US | disclosed |
| US-20090118268-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | RIEDL BERND | 2009-05-07 | — | — | US | disclosed |
| US-20090023669-A1 | Antibacterial Agents | ALCHEMIA LIMITED (AU) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121276-A1 | HISTONE ACETYLTRANSFERASE MODULATORS AND USES THEREOF | EP300, KAT2A, HTT | KDR 4841/4885PDK1 2814/4885TRPV1 3939/4885 |
| US-20150191467-A1 | AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME | SRC, PTPRCAP, GRB2 | KDR 1107/4885PDK1 2591/4885TRPV1 3240/4885 |
| US-20090118268-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | MAPK1, MAPK8, MAPK3 | KDR 2141/4885PDK1 2362/4885TRPV1 3431/4885 |
| US-20140200239-A1 | AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME | SRC, PTPRCAP, GRB2 | KDR 1107/4885PDK1 2591/4885TRPV1 3240/4885 |
| US-20090023669-A1 | Antibacterial Agents | MRPL21, FUT6, FUT5 | KDR 4705/4885PDK1 2776/4885TRPV1 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.